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ABSTRACT
Objectives: The objective of our study was to determine effects of science-based
communications on attitudes toward pneumococcal vaccination and understand how non-white
racial and ethnic populations respond to these messages.
Design: Our team tested several science-based communications using a nationally
representative survey and validated in a local community pharmacy as a field experiment.
Setting/Participants: The nationally representative sample phase was a survey of 3,276
participants, conducted by leading online survey firm YouGov. The field experiment was
conducted at a community pharmacy in the northeastern United States and included 86
participants.
Outcome measures: In the national survey, participants were assigned to treatment groups or a
control group to determine the effects of messaging strategies on influencing favorable views of
pneumococcal vaccination. In the field experiment, participants were assigned to treatment or
control groups to determine if the messaging strategies impacted intent to ask a medical
professional about the vaccine.
Results: The nationally representative survey identified safety-focused vaccine messaging had
statistically significant treatment effects towards increasing individuals’ perception of personal
importance to have the vaccine in the white population, but not in the non-white population (6.2%
vs 2.7%). Messaging that focused on community and family duty demonstrated significant effects
in both populations (8.8% vs 12.2%). These results were validated through the field experiment,
which showed that a combination message emphasizing duty increased individual intent to
vaccinate by 25% in a diverse ethnic population compared to the control.
Conclusions: Messaging focused on appeals to community and family duty produced significant
increases in favorable attitudes toward pneumococcal vaccines and behavioral intent to seek
medical advice about the vaccine in white and non-white populations across both the nationally
representative survey and the field experiment. Medical professionals should highlight duty to

2

family and community when communicating with patients, as it may motivate vaccination in all
populations.

Key Points: Pneumococcal Infection, Invasive Pneumococcal Disease, Pneumococcal Vaccine,
Vaccination, Healthcare Disparities, Health Communication
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1

BACKGROUND

2

Pneumococcal disease is a substantial public health burden among adults in the United States.

3

National estimates for invasive pneumococcal disease in 2016 were 33,400 cases and 3,690

4

resultant deaths.1 The major disparities in pneumococcal vaccination rates between non-white

5

and white adult populations are troubling; in the 2017 National Health Interview Survey,

6

vaccination coverage among black and Hispanic respondents ≥65 years old was at least 15

7

percentage points lower than white respondents.2 The burden of pneumococcal disease in the

8

non-white population is significant due to lower vaccination rates coupled with a high

9

prevalence of pneumococcal risk conditions, such as asthma, diabetes, cardiovascular disease,

10

and stroke.3-6 Correcting for racial disparities in access and quality of health care does not

11

eliminate the pneumococcal vaccination coverage gap.7 Researchers need to consider other

12

key factors, such as attitudes towards vaccination, when shaping efforts to close the gap in

13

pneumococcal vaccination rates between racial and ethnic groups. The National Foundation

14

for Infectious Diseases has called for approaches that identify and overcome attitudinal barriers

15

to adult pneumococcal vaccination in racially and ethnically diverse subpopulations.3 Many

16

vaccine promotion materials currently utilize standard messaging in a “one size fits all” approach

17

that is not sufficient for overcoming negative attitudes.8-10 Therefore, to reduce vaccination

18

disparities across racial and ethnic groups, researchers and healthcare providers need to

19

ensure that messaging and communication intended to influence attitudes toward vaccines

20

resonate among both white and non-white populations.

21

Using both a nationally representative sample and a field experiment, our team tested several

22

science-based communications on attitudes towards pneumococcal vaccinations, with an

23

emphasis on understanding how non-white racial and ethnic populations respond to these

24

messages.

25
26

OBJECTIVE

4

27

The objective of this study was to test science-based communications on attitudes toward

28

pneumococcal vaccination to identify effective messaging in non-white racial and ethnic

29

populations.

30
31

METHODS

32

Study Design

33

This research study was carried out in two stages. First, we conducted a randomized

34

experiment embedded within a nationally representative opinion survey contrasting 5 different

35

messages compared to no message in the control group. The findings from this nationally

36

representative experiment were then used to develop a randomized field experiment undertaken

37

in a community pharmacy. In the field study, there were 2 messages compared to an active

38

control message based on responses from the opinion survey. Treatment messages were

39

designed by utilizing language from the Centers for Disease Control (CDC), reviewing literature

40

on traditional vaccine messaging, and conducting pre-testing of messages for clarity. This study

41

was approved by the University of Rhode Island’s Institutional Review Board.

42
43

National Survey Experiment

44

We contracted with YouGov (https://today.yougov.com, London, UK), a leading online survey

45

firm, to conduct a nationally representative online survey from May 4th - 25th, 2017.11 YouGov

46

is a survey organization that draws on an online community of compensated users (aged 18+)

47

who participate in surveys to voice their opinions. The data collected is utilized by

48

organizations, institutions, campaigns, news media outlets, and companies. Participants are

49

pre-screened to determine criteria they meet for specific surveys and polls. Our nationally

50

representative online survey was conducted in English. The respondents were matched to an

51

appropriate sampling frame on gender, age, race, education, party identification, political

52

ideology, and political interest. The frame was constructed using the 2010 American Community

5

53

Survey, the 2010 Current Population Survey, and the 2007 Pew Religious Life Survey. YouGov

54

distributed the survey to participants and 3,276 people completed the survey. They were then

55

matched down to a sample of 3000 to produce the final dataset. Matching is a method designed

56

to produce representative samples from respondent pools that are not selected randomly. The

57

purpose of this methodology is to produce a respondent sample with the same characteristics

58

and properties as a true random sample of the target population. YouGov matching procedures

59

involve first identifying the target sample and then selecting respondents from the pool of opt-in

60

participants that match members of the target sample. Drawing from an extensive number of

61

variables drawn from voter and consumer databases, YouGov uses a proximity matching

62

method which generates a distance function for each variable used to assess respondent

63

similarity. Using this method, YouGov then identifies opt-in respondents who are most similar to

64

each individual in the target sample. YouGov’s online surveys and matching techniques

65

compare favorably with older and more traditional survey methods.12 The dataset includes a

66

general population sample with a black and Hispanic oversample. The result is a near equal

67

number of white and non-white respondents, which, unlike most studies, allows for the robust

68

evaluation of the treatments effects within a non-white population.a

69

An experiment was embedded into the national survey, with survey respondents randomly

70

assigned to one of five treatments or a control group (Table 1). Embedding randomized

71

experiments in a nationally representative survey has distinct advantages. Because the

72

experiments use a nationally representative sample for the subject pool, rather than a narrower

73

pool of subjects (e.g., college sophomores), the results of the analysis display a high degree of

74

external validity. All treatments began with the statement “Please read the following information

75

carefully before answering the question” followed by the respective persuasive message below.

76

The control group did not receive any message. After being randomly assigned to receive one

The statistical power for tests using the national survey in this study is 99.6% which is well above the
standard for statistical power (80%) (Cohen 1988).14
a
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77

of the treatments or the control group (Table 1), respondents were asked the following, which

78

represents the dependent variable:

79

“If allowed by your healthcare professional, how important is it for you to have the

80

pneumococcal vaccine?” Responses included Very important; Somewhat important; Not very

81

important; Not at all important; Don’t know.

82

Field Experiment

83

To address the concern that revealed attitudes about the importance of the pneumococcal

84

vaccine in an online national survey may not correspond to real world preferences, we also

85

conducted a field experiment at a community pharmacy. The field experiment assessed whether

86

science-based communication could influence openness to vaccination if the messages were

87

introduced in a typically occurring pharmacy practice. We selected a community pharmacy in

88

the northeastern United States that primarily services diverse ethnic and racial communities to

89

test the efficacy of the messages within this context. Corporate approval to conduct the field

90

experiment was obtained. Customers of the community pharmacy were recruited, in English or

91

Spanish, to voluntarily participate in the anonymous survey from April 2018 to May 2018.

92

Qualtrics software version 04.2018 (Qualtrics, Provo, UT) was used to deliver the randomized

93

messages, either the active control or one of two treatments (Table 2), and record the

94

responses. The participant could select to take the survey in English or Spanish, which

95

established greater external validity for the findings from the national survey experiment,

96

especially for non-English speaking communities. The field experiment included 86 participants.

97

After being randomly assigned to receive one of the above-mentioned conditions, subjects then

98

were asked the following, which represents the dependent variable:

99

If you were to talk to your doctor or pharmacist today, would you ask about getting the

100

pneumococcal vaccine? Yes; No

101
7

102

Analysis. Both the national survey experiment and field experiment had more than two

103

conditions, therefore we used one-way analysis of variance (ANOVA) to determine whether the

104

groups had significantly different attitudes about the pneumococcal vaccine. Two-sided

105

hypothesis tests were used for all P values, and the α<0.05 threshold was used to define

106

statistical significance. Percentage point difference relative to the control group was calculated

107

across treatments for those participants responding “Somewhat important” or “Very important” in

108

the national survey experiment and those responding “Yes” in the field experiment. Results

109

from the national survey experiment were differentiated by race (non-white, white) in order to

110

identify messages that were effective in non-white populations and could then be tested in the

111

field experiment. All analyses were conducted using STATA version 15 (StataCorp, College

112

Station, TX).13

113
114

RESULTS

115

The demographic characteristics of the subjects in each treatment and control group for the

116

national survey experiment and field experiment are described in Table 3. The groups were

117

homogenous for all demographic characteristics, as none of the differences across treatments

118

are significant at the α<0.05 level. To alleviate any concerns that education and gender

119

differences were significantly influencing our results in the field experiment, we conducted

120

additional analyses using ANOVA and OLS regression controlling for education and gender

121

(both separately and together) and found no substantive differences to the results presented

122

below.

123
124

National Survey Experiment Results

125

The national survey experiment results are presented in Table 4. Among non-whites, treatment

126

messages 1 (prevention), 2 (costs), and 3 (safety) did not significantly influence favorable views

127

of pneumococcal vaccination in comparison to the control group, which received no message.

8

128

For non-whites, messaging that simply states the vaccine helps prevent pneumonia (T1),

129

messaging that considers various costs including mortality, health, lost work, and expense of

130

the vaccine (T2) as well as messaging that centers on assurances of vaccine safety (T3) do not

131

appear to influence attitudes beyond baseline attitudinal predispositions as measured in the

132

control group. Among non-whites, message treatments 4 (community and family duty) and 5

133

(combination message) did significantly influence favorable views of pneumococcal vaccination

134

in comparison to the control group. These messages focusing on duty towards community and

135

family (T4) and a combined message that involves the key elements from all of the other

136

messages (T5) had significant effects on favorable vaccination attitudes (see Table 5). Results

137

demonstrated 86.6% of subjects receiving the T4 message about duty to family and community

138

responded that the pneumococcal vaccine was somewhat or very important, which was 12.2

139

percentage points higher than the control group. The combined message group showed a

140

similar difference as compared with the control group, with 84.3% responding that the vaccine

141

was somewhat or very important (9.9 percentage points higher than control).

142

Among whites, message treatments 1 (prevention) and 2 (costs) did not significantly influence

143

favorable views of pneumococcal vaccination in comparison to the control group that received

144

no message. In Table 5, we see that messaging that simply states the vaccine helps prevent

145

pneumonia (T1) and messages that consider various costs (T2) did not influence attitudes

146

beyond baseline predispositions. Among whites, message treatments 3 (safety), 4 (community

147

and family duty), and 5 (combination message) did significantly influence favorable views of

148

pneumococcal vaccination in comparison to the control group. These messages focusing on

149

assurances of safety (T3), duty towards community and family (T4), and a combined message

150

(T5) had similar substantive effects on favorable pneumococcal vaccination attitudes (see Table

151

3). Relative to the control group, the safety message (T3) and the combined message (T5) had

152

a greater percentage of respondents responding that the vaccine was somewhat or very

153

important, 6.2 and 6.3 percentage points higher respectively. The duty message (T4), relative to

9

154

the control group, also displayed more favorable vaccination attitudes, with an 8.8 percentage

155

point difference. It should be noted that safety messages did have a treatment effect in non-

156

white populations (2.7%), but the increase was not statistically significant (p-value of 0.628).

157
158

Field Experiment Results. Table 6 displays the ANOVA for the field experiment undertaken at

159

a northeastern U.S. pharmacy, which was selected because it serves a predominantly non-

160

white population. The Treatment 1 message explains that pneumonia, bacteremia and

161

meningitis are leading causes of death (fatality), that the pneumococcal vaccine helps prevents

162

these diseases, and that the vaccine is safe and easy to get (safety). Relative to the control

163

group message that simply states that the pneumococcal vaccine decreases the risk of

164

pneumonia, bacteremia and meningitis, exposure to Treatment 1 did not significantly influence

165

the intention of participants to ask their medical professional about the pneumococcal vaccine.

166

The Treatment 2 message started with the same content as Treatment 1, but also added a duty

167

to others component, which stated that getting the pneumococcal vaccine was a way to be

168

responsible and protect the health and life of friends, family and the community. Unlike

169

Treatment 1, exposure to the Treatment 2 duty message did significantly influence the intention

170

of participants to ask their medical professional about the pneumococcal vaccine. Table 7

171

shows that 67.6% of the control group indicated an intention to ask their medical professional

172

about the pneumococcal vaccine whereas 92.3% of Treatment 2 subjects declared an intention

173

to ask their medical professional about the vaccine, a difference of 24.7 percentage points

174

between the control and treatment 2.

175
176

DISCUSSION

177

From a national survey, we identified that effective messaging for pneumococcal vaccination in

178

white and non-white populations included duty to family and community. The message was

179

then adapted and tested in a predominantly non-white community pharmacy. Results from the

10

180

field test show that a combined message focused on fatality, safety, and duty to family and

181

community was found to be highly effective, increasing intent to vaccinate by 25%. In Hispanic

182

patients ≥65 years old, messaging about duty to family and community could help close the

183

22.2% vaccination gap compared to white patients identified in the National Health Interview

184

Survey in 2017.2

185

In our national survey experiment, the safety focused message treatment shows the importance

186

of conducting studies with a large non-white population rather than general populations.

187

Treatment 3’s safety-focused message demonstrated a statistically significant treatment effect

188

of 6.2% in whites but a non-significant effect of only 2.7% in non-whites. These results convey

189

that while safety messages positively influence vaccination attitudes for whites, they may not

190

have as significant effects for non-whites. Though the vaccine safety debate is popular in the

191

press and in some vaccine promotion campaigns, an exclusive focus on safety when

192

communicating about the vaccine may actually exacerbate vaccination rate disparities

193

unintentionally. The field experiment confirms the importance of including family and duty

194

messaging when promoting vaccination in pharmacies that serve diverse populations. We were

195

limited in what we could ask in the field experiment, so we used CDC messaging as a control,

196

since that is typically encountered in a community pharmacy.

197

Recent research has shown that US clinicians view non-whites as less likely to follow health and

198

medical recommendations, which may decrease the odds of clinicians communicating the types

199

of messaging interventions considered in our study. But, our results show that non-whites

200

targeted with messaging about the pneumococcal vaccine display large positive effects in

201

vaccination attitudes, as demonstrated in the national survey experiment with messages that

202

target duty to community and family (T4 and T5). At the practice level, particularly in areas that

203

serve heterogeneous racial and ethnic populations, medical professionals should take the time

204

to talk about vaccines with their patients. Specifically, targeting messaging of duty towards

205

others can be especially efficacious in shaping attitudes in all people, but it may have the

11

206

greatest impact in non-white communities. A limitation of our study was that we only assessed

207

intention to ask a healthcare professional about the vaccination and did not assess the actual

208

action.

209

Ideally, multiple field experiments across the nation would capture a broader sample of non-

210

white communities. According to 2010 census data, the pharmacy for the field experiment was

211

conducted in an area with a higher level of racial diversity (60% non-white population) than the

212

rest of the state (15% non-white population).

213

Though the final question on the instrument identified if participants would ask their doctor or

214

pharmacist about getting the pneumococcal vaccine, it is unknown if they actually did speak to

215

these health professionals, or ultimately receive the vaccination. Due to small numbers, the

216

field experiment did not assess treatment effect by race.

217

CONCLUSION

218

In this study, it was found that in both white and non-white populations combined messaging

219

emphasizing appeals to communal and family duty produced substantively significant

220

differences in favorable attitudes toward pneumococcal vaccines in the nationally representative

221

survey and behavioral intent to seek medical advice about the pneumococcal vaccine in a field

222

experiment at a northeastern U.S. pharmacy. Medical professionals should use vaccine

223

messaging that emphasizes duty to family and community when communicating with patients,

224

as it reduces attitudinal and behavioral disparities. Our results indicate that some popular

225

vaccine messaging interventions increase openness to receiving pneumococcal vaccination

226

only among white populations while other messaging interventions have positive effects on both

227

white and non-white populations.

228

Future research will need to confirm results in broader representations of non-white

229

communities. In addition to marketing messages, there is an opportunity for development of

12

230

visuals that include appeals to family and community duty as part of public health marketing

231

strategy. Lastly, clinical outcomes demonstrating increased adult pneumococcal vaccination

232

coverage in non-white communities are needed to confirm the impact of this messaging.

233
234
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Table 1. Messages used in the national survey experiment
Treatment Messages
Treatment Group
Number

Focus Area

Message

Treatment 1

Pneumonia
Prevention

Treatment 2

Costs

Treatment 3

Safety of Vaccine

Treatment 4

Community & Family
Duty

The pneumococcal vaccine is highly effective at
preventing pneumonia.
In the United States, pneumonia is a leading
cause of death, with over 50,000 people dying
from pneumonia each year. Pneumonia also
causes severe sickness leading to bed rest,
hospitalization and missing work. Cigarette
smokers, older adults, those with asthma or
COPD are most susceptible to pneumonia.
Fortunately, pneumonia can be prevented by the
highly effective pneumococcal vaccine. Even if
you are currently healthy, had pneumonia in the
past, or had the flu shot you still need the
pneumococcal vaccine to be protected. It is free,
quick and easy to get the pneumococcal vaccine
from most health providers.
The pneumococcal vaccine is highly effective at
preventing pneumonia and the pneumococcal
vaccine has been thoroughly tested for safety by
independent medical doctors and scientists.
Years of evidence strongly show that sickness
and side effects from the pneumococcal vaccine
are incredibly rare. The pneumococcal vaccine is
considered very safe.
It is everyone’s duty to eliminate contagious
disease from our communities. Those receiving
the pneumococcal vaccine contribute to
everyone’s good health by helping to eradicate
pneumonia. This simple act of getting the
pneumococcal vaccine protects family, friends and
our community because vaccinated individuals will
be less likely to infect others with pneumonia.
Being responsible and caring for those around you
means getting vaccinated.

15

Treatment 5

Combined Message

In the United States, pneumonia is a leading
cause of death, with over 50,000 people dying
from pneumonia each year. Pneumonia also
causes severe sickness leading to bed rest,
hospitalization and missing work. Cigarette
smokers, older adults, those with asthma or
COPD are most susceptible to pneumonia.
Fortunately, pneumonia can be prevented by the
highly effective pneumococcal vaccine. Even if
you are currently healthy, had pneumonia in the
past, or had the flu shot you still need the
pneumococcal vaccine to be protected. It is free,
quick and easy to get the pneumococcal vaccine
from most health providers. The pneumococcal
vaccine has been thoroughly tested for safety by
independent medical doctors and scientists.
Years of evidence strongly show that sickness
and side effects from the pneumococcal vaccine
are incredibly rare. The pneumococcal vaccine is
considered very safe.It is everyone’s duty to
eliminate contagious disease from our
communities. Those receiving the pneumococcal
vaccine contribute to everyone’s good health by
helping to eradicate pneumonia. This simple act of
getting the pneumococcal vaccine protects family,
friends and our community because vaccinated
individuals will be less likely to infect others with
pneumonia. Being responsible and caring for
those around you means getting vaccinated.

16

Table 2. Messages used in the field experiment.
Field Experiment Messages
Group

Focus

Control

Risk

Treatment 1

Fatality & Vaccine Safety

Treatment 2

Fatality, Safety, and Duty

Message
The pneumococcal vaccine is highly effective at
decreasing the risk of pneumonia, bacteremia and
meningitis.
Pneumonia, bacteremia and meningitis are leading
causes of serious disease and death. Fortunately,
the pneumococcal vaccine decreases the risk of
pneumonia, bacteremia and meningitis. The
vaccine is safe, quick and easy to get.
Pneumonia, bacteremia and meningitis are leading
causes of serious disease and death. Fortunately,
the pneumococcal vaccine decreases the risk of
pneumonia, bacteremia and meningitis. The
vaccine is safe, quick and easy to get.Getting the
pneumococcal vaccine also protects your family,
friends and community because you will be much
less likely to infect others. Vaccination is one of the
best ways to be responsible and care for the health
and life of those closest to you.

17

Table 3. Demographic comparisons across experimental groups
Treatment Group:
National Survey Experiment
Overall Control T1
T2
T3
T4
T5
46.1
46.9
45.5 46.9 45.1 46.2 46.3

Treatment Group:
Field Experiment
Overall Control T1
T2
45.4
43.1
46.8 46.8

Age (mean)
Gender (%
55
56
57
54
54
57
53
69
74
female)
Education (%
23
23
24
22
22
22
23
20
15
college or more)
Income (%
27
24
27
26
26
28
28
$50,000-99,999)
Rural (%)
20
21
19
20
20
20
20
N
3000
513
520 496 482 482 507
86
34
Note: None of the differences across treatments are significant at p < .05 based on a oneway analysis of variance.

18

58

73

19

27

26

26

Table 4. National survey experiment analysis of variance of the effect of messaging on
pneumococcal vaccination importance, stratified by race
Non-Whites
Whites
Main effects
Main effects
Treatment Conditions
N
F
p
N
F
p
Control
211
N/A
N/A
186
N/A
N/A
Pneumonia Prevention
219
0.13
0.716
240
0.07
0.791
Costs
208
1.1
0.295
238
1.69
0.193
Safety of Vaccine
205
0.23
0.628
225
4.32
0.038
Community & Family Duty
209
7.31
0.007
203
4.34
0.037
Combined Message
229
11.32
0.001
235
4.07
0.044
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Table 5. National survey experiment treatment effects of messaging on pneumococcal
vaccination importance, stratified by race
Non-Whites

Whites

Treatment
Treatment
Treatment Conditions
N
% Important
Effect
N
% Important
Effect
Control
211
74.4%
N/A
186
72.0%
N/A
Pneumonia Prevention
219
71.2%
-3.2%
240
71.7%
-0.3%
Costs
208
80.3%
5.9%
238
77.3%
5.3%
Safety of Vaccine
205
77.1%
2.7%
225
78.2%
6.2%
Community & Family Duty 209
86.6%
12.2%
203
80.8%
8.8%
Combined Message
229
84.3%
9.9%
235
78.3%
6.3%
Note: Bold indicates a statistically significant effect in the analysis of variance (Table 4).
% Important includes all "Somewhat Important" and "Very Important" responses.
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Table 6. Field Experiment Analysis of Variance of the Effect of Messaging on Pneumococcal
Vaccination Intent
Main effects
Treatment Conditions
Control
Fatality & Vaccine Safety
Fatality, Vaccine Safety, & Duty

N
34
26
26

F
N/A
1.58
5.58

p
N/A
0.212
0.021
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Table 7. Field experiment treatment effects of messaging on pneumococcal vaccination
importance
Treatment Conditions
N
% Agree to Ask
Treatment Effect
Control
34
67.6%
N/A
Fatality and Vaccine Safety
26
80.8%
13.2%
Fatality, Vaccine Safety, and Duty
26
92.3%
24.7%
Note: Bold indicates a statistically significant effect in the analysis of variance (Table 6).

22

